Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alexion Pharmaceuticals, Inc.    ALXN   US0153511094

 SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
12/11/2014 12/12/2014 12/15/2014 12/16/2014 12/17/2014 Date
191.62(c) 186.9(c) 183.21(c) 177.73(c) 182.08(c) Last
1 038 443 1 041 028 1 375 952 1 933 206 1 953 673 Volume
+0.09% -2.46% -1.97% -2.99% +2.45% Change
More quotes
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, engages in the innovation, development, and commercialization of life-transforming therapeutic products for treating patients with severe and ultra-rare disorders.It focuses on developing products for the treatment of diseases in the... 
Sector
Pharmaceuticals
Calendar
02/12Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Chart ALEXION PHARMACEUTICALS, I
Duration : Period :
Alexion Pharmaceuticals, I Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Financials ($)
Sales 2014 2 227 M
EBIT 2014 1 117 M
Net income 2014 725 M
Finance 2014 1 761 M
Yield 2014 -
Sales 2015 2 733 M
EBIT 2015 1 364 M
Net income 2015 948 M
Finance 2015 2 897 M
Yield 2015 -
PER 2014 51,16
PER 2015 38,36
EV / Sales 2014 15,4x
EV / Sales 2015 12,1x
Capitalization 36 104 M
More Financials
Latest news on ALEXION PHARMACEUTICALS, I
2h ago ALEXION PHARMACEUTICALS : New Data Presented at ASH Annual Meeting Enhance Clini..
3d ago ALEXION PHARMACEUTICALS : Soliris (eculizumab) Secures Orphan Drug Designation
3d ago ALEXION PHARMACEUTICALS : Other Events, Financial Statements and Exhibits (form ..
3d ago ALEXION PHARMACEUTICALS : Announces $500 Million Share Repurchase Program
7d ago ALEXION PHARMACEUTICALS : UConn Stem Cell Institute, Alexion team up to find new..
12/10 ALEXION PHARMACEUTICALS : Soliris® (eculizumab) Granted Orphan Drug Designation ..
12/10 ALEXION PHARMACEUTICALS : Soliris® (eculizumab) Granted Orphan Drug Designation ..
12/09 ALEXION PHARMACEUTICALS : Soliris (eculizumab) Gets Orphan Drug Designation
More news
Sector news
12m ago GSK shareholders approve asset swap deal with Novartis
23m ago PFIZER : Reports Top-Line Results From a Phase 3 Study Evaluating Pregabalin Con..
47m ago France fines household product firms 951 million euro for price fixing
More sector news


Comments 
Advertisement
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF